Purpose Meningiomas are a frequent tumor of the central nervous system. Although mostly benign, approximately 5% present as atypical or malignant tumors. Treatments for atypical meningiomas include gross total resection and radiotherapy, but about 33% of patients have recurrent tumors, sometimes as a higher grade. Recently, the brain penetrant anthelmintic drug, mebendazole, has shown promise as an anticancer agent in rodent models of glioblastoma and medulloblastoma. Methods The half maximal inhibitory concentration (IC 50 ) effect on colony formation, cell proliferation, and caspase-3/7 markers of apoptosis of mebendazole with and without radiation was measured in vitro. Mice intracranially implanted with KT21MG1 human meningioma were administered mebendazole alone or in combination with radiation. Survival benefit was evaluated, while tumors were investigated by immunohistochemical staining for apoptosis, cell proliferation, and vascular density. Results In vitro experiments on meningioma cell lines showed the IC 50 for mebendazole in the range of 0.26-0.42 µM. Mebendazole alone induced cytotoxicity, however the combination had a greater reduction in colony formation and resulted in higher levels of cleaved caspase-3. The in vivo study showed both, mebendazole alone and the combination, to have a survival benefit with an increase in apoptosis, and decreases in tumor cell and vascular proliferation. Conclusion These preclinical findings indicate that mebendazole alone or in combination with radiation can be considered for the treatment of malignant meningioma. The mechanism of action for this combination may include an increase in apoptosis, a reduction in proliferation and angiogenesis, or a combination of these effects.
Introduction
Tumors of the meninges accounting for 35% of adult brain tumors [1] . Most meningiomas are benign and respond to surgical resection and/or radiation therapy [2, 3] . However, patients with the worst meningiomas, Grade III malignant have poor survival with few or no treatment options [2] . For recurrent meningiomas, which are found mostly in the Grade II and III, systematic chemotherapy [3, 4] , α-interferon [5] , somatostatin analogues [6] , or VEGF inhibitors [7] have all been attempted, but with little success.
Recently, drug repurposing has been investigated for the treatment of colon cancer [8, 9] liver cancer [10] , breast cancer [11] , prostate cancer [12] , and small cell lung cancer [13] . Mebendazole, an antiparasitic benzimidazole, has long been in worldwide use to treat helminthic infections, primarily pin, round and hook worms [14] . It is also used to treat central nervous system parasitic infections such as echinococcosis and neurocysticercosis [15, 16] . Mebendazole's mechanism depends in part on binding to alpha-tubulin to disrupt microtubule formation, leading to cytoskeletal instability [17] . Mebendazole is regarded as a relatively non-toxic drug and demonstrates antitumor activity in several types of malignancies [8, [18] [19] [20] . In glioblastoma [17] and medulloblastoma [21] [22] [23] animal models, mebendazole increased 1 3 median survival. Other potential mechanisms that might contribute to survival benefit was an observed decrease in tumor angiogenesis, through the inhibition of vascular endothelial factor receptor 2 (VEGF2) [21] , inhibition of the hedgehog pathway [22] , and increased caspase-3 pathway activity [22] .
Beyond surgery, radiation is the only routinely used therapy for the treatment of malignant meningioma, but there is much room for improvement. Patients with WHO Grade II or III meningioma treated with radiation in doses ranging from 44 to 66 Gy had a 5 year overall survival of 30% and 0%, respectively [24] . In a different study, patients with atypical meningioma treated with external beam radiation therapy had a 5 year progression free survival rate of 65%, but with subtotal resection, only 30% [25] . In preclinical studies of malignant meningioma the effects of radiation appear to be mixed and cell line dependent [26] [27] [28] .
Here, we find that mebendazole alone and in combination with radiation decreases cell viability and induces apoptosis via the caspase-3/7 pathway in human cell lines of malignant meningioma. Furthermore, the combination increased median survival by inducing apoptosis, decreasing cell proliferation and angiogenesis in an intracranial rodent model of malignant meningioma.
Materials and methods

Cell lines and cell culture
Cell lines (KT21MG1, IOMM LEE, AC-1, SF4068, SF6717, SF1335, SF1335 + YAP) (Supplementary Table 1) were initially transfected with the hTERT vector for immortalization [29] [30] [31] . Cell lines were grown in DMEM supplemented with 10% fetal bovine serum and 1% penicillin/ streptomycin at 37 °C with 5% CO 2 .
Cell viability, proliferation, survival, and apoptosis assays
Cell lines were plated in a 96-well plate at 2000 cells per well. 24 hours after plating, the cells were treated with a range of mebendazole concentrations (0.001-100 µm) or a single dose of radiation (12 Gy) and incubated for an additional 72 h. Radiation dosing was achieved by the CIXDXstrahl System using the VWP-1 Software Package. Cell viability and half maximal inhibitory concentrations were calculated using the Cell Counting Kit-8 (Dojindo Molecular Technology, Japan). A Cell proliferation ELISA kit (Roche, Indianapolis, IN, USA) was used to measure bromodeoxyrudine (BrdUrd) incorporation according to manufacturer instructions. For clonogenic survival, KT21MG1 and IOMM LEE cells were seeded (1 × 10 2 ) and (2 × 10 2 ) into 6-well plates, respectively. After a 24 h incubation, cells were treated with mebendazole for 72 h. Colony formation was stained with 0.2% crystal violet and counted under a microscope. For the evaluation of apoptotic activity, KT21MG1 and IOMM LEE cells were treated with mebendazole for 72 h with and without radiation (12 Gy) via the CIXD after 24 h of mebendazole treatment, and evaluated by the Caspase-Glo 3/7 assay (Promega, G8091).
Immunohistochemistry and western blotting
Immunohistochemistry [30] 
Animal experiments
Six week old female athymic mice were anesthetized and using a stereotactic frame, 50,000 KT21MG1 cells expressing luciferase lentivirus [33] in 0.5 µL matrigel matrix were implanted into the skull base 2 mm posterior to the bregma, 2 mm to the right of the bregma, and 5.8 mm below the skull surface as previously described [34] . The description of the cell line can be found in Supplementary Table 1 .
At day 5-post implantation of the KT21MG1 cells, mebendazole was administered in a high fat (45 kcal% fat from soybean oil and lard) mouse diet [18] (Research Diets, New Brunswick, New Jersey, USA) that was available for the mice ad libitum at a dose of 50 mg/kg/day MBZ until the end of the experiment [17] . Control animals were fed the high fat pellet diet without mebendazole. The mice were monitored daily ( Supplementary Fig. 1 ) and euthanized if neurological symptoms occurred or weight loss exceeded ≥ 15%. Survival was measured from day of implantation to euthanasia.
At day 5-post implantation the mice were treated with local radiation therapy by the Small Animal Radiation Research Platform (SARRP) [35] using a single dose of 12 Gy of radiation at a beam width of 3 mm × 3 mm. Using CT-Spot software (Beeley Medical, Bristol, CT) the burr hole in the skull from implantation was located. The decision to administer a single dose of 12 Gy radiation was based the successful application of this treatment in an intracranial model of NF2 mutant malignant meningioma.
Intracranial luciferase activity from tumor cells was observed by the Xenogen IVIS. Each mouse was administered D-luciferin potassium salt (Gold Biotechnology, St. Louis, MO, USA) in dPBS and analyzed in overlay mode with Living Image Software.
Statistical analysis
Graph Pad Prism 5 Software was used for statistical analysis as previously described [30] , with p values determined by a Mantel-Cox test. A one-way ANOVA followed by a Tukey Test compared groups (p ≤ 0.05) considered statistically significant. A two-way ANOVA with a Bonferroni post-test determine significance (p ≤ 0.05) by comparing treatment groups among cell lines. A two-tailed unpaired t test compared luminescent imaging.
Results
Mebendazole and its combination with radiation is effective in a malignant meningioma model
The KT21MG1 intracranial mouse model of malignant meningioma was used to test the in vivo efficacy of mebendazole alone and in combination with radiation. Five days after tumor implantation mice were administered mebendazole premixed in a high fat (HF) diet. Food consumption revealed that the mice ingested a dose of 50 mg/kg mebendazole. Our laboratory has previously shown that a dose of 12 Gy reduces xenograft tumor growth of malignant meningioma in vivo. Figure 1 represents the combined survival curve and luminescence data from two animal experiments conducted separately to show reproducibility of treatment effect. As Fig. 1a shows, the mice in the mebendazole group had a significant increase in median survival of 58% in comparison to the control (19 days versus 30 days, p ≤ 0.0001), while the mice administered the combination of mebendazole and a single dose of radiation (12 Gy) had a significant increase in median survival of 105% when compared to the control (19 days versus 39 days, p ≤ 0.0001). The increase in median survival in the combination group was significant to the group administered mebendazole (30 days versus 39 days, 30% increase, p = 0.0005), and radiation alone (33.5 days versus 39 days, 16% increase, p = 0.0062).
Luminescence images acquired 12 days after implantation (Fig. 1b, c) illustrated that mebendazole and radiation as single treatments significantly reduced tumor luminescence compared to control (mebendazole versus control, p ≤ 0.01 and radiation versus control, p ≤ 0.001). Radiation has been shown to reduce tumor growth in intracranial models of meningioma, alone and in combination with anticancer agents [28] . Tumor growth in the brain was significantly delayed by the combination of mebendazole and radiation when compared to the control (combination versus control, p ≤ 0.001), or mebendazole alone (combination versus mebendazole, p ≤ 0.05), but not to radiation alone (combination versus radiation, p ≥ 0.05) (Fig. 1c) .
Mebendazole and its combination with radiation decreases cell proliferation and angiogenesis, and increases apoptosis
To evaluate the survival activity observed in the intracranial mouse model, we analyzed and compared protein expression in brain tumors from mice given mebendazole at 50 mg/ kg body weight, 12 Gy radiation only, and the combination of both treatments versus the untreated control. By hematoxylin and eosin staining, we confirmed tumor growth of the KT21MG1 xenograft in all four treatment groups. Histological evaluation of tumors revealed that the tumors from animals administered mebendazole or the combination were smaller in size compared to tumors from the control and radiation groups, which correlated with the decrease in bioluminescence observed during in vivo imaging. Overall, mebendazole alone and in combination with radiation decreased tumor size in our animal model (Fig. 2) .
We evaluated the expression of cleaved caspase-3, a marker of apoptosis, since this pathway has been shown to be activated by mebendazole [22] . Immunohistochemical staining revealed low cleaved caspase-3 expression in radiation and control groups. We observed moderate expression of cleaved caspase-3 in the mebendazole only group and the highest levels of cleaved caspase-3 expression (Fig. 2) in the combination group. Immunohistochemical staining for Ki67 confirmed the combination decreased cell proliferation in tumors compared to control and single treatment groups.
Mebendazole has shown to decrease tumor angiogenesis in animal models of medulloblastoma [21] and colon cancer [18] . The CD31 protein is a useful marker for evaluation of tumor vasculature, or angiogenesis [36] . Our data illustrated that brain sections of mice treated with mebendazole alone had reduced expression of CD31 protein by immunohistochemical analysis. The expression of CD31 was further reduced in the combination group when compared to the control, or either treatment group alone, but was not significant (Fig. 2) .
The combination of mebendazole with radiation decreases survival and cell viability in malignant meningioma cell lines
A panel of human meningioma cell lines with varied WHO Grade and NF2 mutational status (Supplementary Table 1) were used to further investigate if mebendazole alone and in combination with radiation influence proteins involved cell proliferation and apoptosis in vitro. Mutations in the NF2 (neurofibromatosis Type-2 gene) have shown to increase malignancy of recurring meningiomas. Merlin, the NF2 protein product, acts as a tumor suppressor in the Hippo Pathway in cases of meningioma.
The human meningioma cell lines treated with mebendazole alone had IC 50 values in the 0.26-0.42 µM range (Fig. 3a) . These IC 50 values are similar to mouse glioma and human glioblastoma cells lines treated with mebendazole [17] . The effects of radiation doses (0-20 Gy) on the viability of meningioma cell lines were examined (Supplementary Fig. 2) . Exposure of meningioma cell lines to 8-10 Gy of radiation has previously shown to induce cell senescence and reduce cell viability [26, 37, 38] . In our study, we found the application of 12 Gy radiation to mebendazole treated cells lowered the IC 50s , but only in Grade III malignant meningioma cell lines, KT21MG1 and IOMM LEE, by 22-33%, respectively.
Clonogenic activity of both cell lines, KT21MG1 and IOMM LEE, was significantly reduced with low doses of mebendazole (0.5-1 µM) in comparison to controls. Mebendazole in combination with radiation (2 Gy) further reduced colony formation compared to either agent alone (Fig. 3b, c) .
Control
A BrdUrd assay was used to measure cell proliferation after exposure to mebendazole with and without radiation (Fig. 4a, b) . For both cell lines we observed a dose Fig. 2 Mebendazole alone and in combination with radiation decreases xenograft tumor growth by altering pathways involved in apoptosis, cell proliferation, and angiogenesis in vivo. Representative brain tissue sections were submitted to hematoxylin and eosin for each treatment group. Brain tissue sections were subjected to immunohistochemical analysis for cleaved caspase-3 (10x), Ki67 (10x), and CD31 (10x) and are illustrated above for all treatment groups. The average protein expression for each treatment group was quantified using ImageJ deconvolution. dependent decrease in proliferation with mebendazole alone and in combination with radiation, compared to the control.
Mebendazole alone or in combination with radiation increases apoptosis in human cell lines of malignant meningioma
The decrease in cell viability observed in response to mebendazole treatment may be a result of activation of apoptotic pathways [10, 22] . The activity of the caspase-3/7 pathway was measured in KT21MG1 and IOMM LEE cells treated with mebendazole alone or in combination with radiation. As illustrated in Fig. 4c , mebendazole increased caspase-3/7 activity in a dose dependent manner alone and in combination with radiation in the KT21MG1 cell line. When the effects of the combination were compared to mebendazole alone at similar doses in the KT21MG1 cell line, significance was not observed. In the IOMM LEE cell line (Fig. 4d ) mebendazole increased caspase-3/7 activity over the control, but only ranging from 0.5 to 10 µM. A similar response in caspase-3/7 activity was observed in the IOMM LEE cell line when the combination was compared to the control. Overall, the effects of the combination were not significant when compared to mebendazole alone in the IOMM LEE cell line. At doses of 50-100 µM caspase-3/7 activity decreased drastically, potentially from drug toxicity. However, the IOMM-LEE cell line had a significant increase in caspase-3/7 activity in comparison to the KT21MG1 cell line, which needs to be further investigated. The effect of mebendazole alone and in combination with radiation on the apoptotic process was further investigated by evaluating the expression of protein markers of apoptosis by western blot analysis (Fig. 5) . The KT21MG1 treated with mebendazole ranging from 0.1 to 1 µM illustrated a dose dependent increase in the cleaved PARP/ PARP ratio, cleaved caspase-3, and cleaved caspase-7 ( Fig. 5a ), while the combination of mebendazole and radiation resulted in a dose dependent increase of cleaved caspase-3, but not cleaved caspase-7. The cleaved PARP/ PARP ratio remained unchanged in response to the combination in the KT21MG1 cell line (Fig. 5b) . In the IOMM LEE cell line the cleaved PARP/PARP ratio, cleaved caspase-3, and cleaved caspase-7 expression increased in a dose dependent manner when treated with mebendazole (Fig. 5c ). The combination increased cleaved caspase-3 and cleaved caspase-7 expression in a dose dependent manner, while the cleaved PARP/PARP ratio remained unchanged (Fig. 5d ).
Discussion
Currently malignant meningiomas are treated with radiotherapy and gross total resection with limited success [39] . The five year median survival of patients ranges from 47 to 61% [3] . Currently, there are no FDA approved chemotherapeutic regimens for malignant meningioma and chemotherapeutics offer limited benefit [3] . The anthelmintic benzimidazole class of compounds have been used for decades for the safe and effective treatment of parasitic infections of the central nervous system. Mebendazole is known to target parasitic infections by binding and disrupting alpha-tubulin in the parasite, leading to death. Efficacy of mebendazole on a broad range of cancer cell lines attribute, at least in part, to activation of cell death pathways [10, 22] . Furthermore, the anticancer effects of mebendazole have been studied in rodent models of colon cancer [18] , medulloblastoma [21] [22] [23] , and glioblastoma [17] , and have shown promising results by impeding different pathways involved in tumor growth. In this study, we show for the first time how mebendazole administration alone or in combination effectively extends survival in preclinical models of malignant meningioma. A dose of 50 mg/kg MBZ plus a single dose of 12 Gy radiation can impede tumor growth and significantly increase survival in a Grade III intracranial model of malignant meningioma by decreasing Ki67 and increasing cleaved caspase-3 protein expression. Mebendazole is known to reduce microvessel density and disrupt the formation of the tumor vasculature by inhibiting VEGFR2 [21] . We evaluated the antiangiogenic activity of mebendazole and radiation by measuring the protein expression of CD31 in brain tumors. Combination treatment resulted in lower levels of CD31, indicative of a decrease in tumor vasculature, consistent with other brain cancer models [21] .
A recent study suggested that mebendazole may sensitize brain cancer cells to radiation by altering the expression of DNA damage response proteins. When glioma cell lines were treated with mebendazole and radiation, γH2AXl, a marker of DNA damage, was increased, while the DNA trafficking proteins Nbs1 and Chk2 were sequestered in the cytoplasm, suggesting the combination impaired DNA damage repair [40] . The combination of mebendazole and radiation seems to have a synergistic effect on inhibiting the DNA damage response. Markowitz et al. hypothesized that disrupting tubulin formation, leads to a decrease in the tubulin transport of key proteins involved in DNA repair [40] . Poruchynsky et al. demonstrated that lung and breast cancer cell lines treated with microtubule-targeting agents plus radiation increased expression of γH2AX, an indicator of DNA damage [41] . Additional studies may be required to demonstrate how mebendazole and radiation mediate disruption of microtubule formation and DNA damage in malignant meningioma.
In summary, our study provides evidence that the combination of mebendazole and radiation can decrease cell growth and angiogenesis and increase apoptosis in preclinical models of malignant meningioma. Due to the safety and experience with mebendazole and radiation, and the lack of effective therapies for malignant meningioma Grade III this should be considered for clinical trials. Additionally, atypical meningiomas Grade II or those Grade I where surgical intervention is not possible, this treatment could also be considered to increase the beneficial effects of radiation therapy.
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